Phaseline

Companies › Hope Biosciences

Hope Biosciences: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology, Genitourinary; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Autologous HB-adMSCs
Autologous adipose-derived mesenchymal stem cells
–Phase 2Traumatic Brain InjuryDec 2027
Allogeneic HB-adMSCs
Allogeneic adipose-derived mesenchymal stem cells
–Phase 1Acute Kidney InjuryJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05951777Autologous HB-adMSCsPhase 2Traumatic Brain InjuryOncologyDec 2027
NCT06654193Allogeneic HB-adMSCsPhase 1Acute Kidney InjuryGenitourinaryJan 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Hrain Biotechnology Marzieh Ebrahimi Beijing Yongtai Ruike Biotechnology Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.